Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer

被引:51
|
作者
Rakaee, Mehrdad [1 ]
Kilvaer, Thomas K. [2 ,3 ]
Dalen, Stig Manfred [4 ]
Richardsen, Elin [1 ,4 ]
Paulsen, Erna-Elise [2 ,3 ]
Hald, Sigurd M. [3 ]
Al-Saad, Samer [1 ,4 ]
Andersen, Sigve [2 ,3 ]
Donnem, Tom [2 ,3 ]
Bremnes, Roy M. [2 ,3 ]
Busund, Lill-Tove [1 ,4 ]
机构
[1] UiT Arctic Univ Norway, Dept Med Biol, N-9019 Tromso, Norway
[2] Univ Hosp North Norway, Dept Oncol, N-9019 Tromso, Norway
[3] UiT Arctic Univ Norway, Dept Clin Med, N-9019 Tromso, Norway
[4] Univ Hosp North Norway, Dept Clin Pathol, N-9019 Tromso, Norway
关键词
TILs; Tumor-infiltrating lymphocytes; NSCLC; Prognosis; Lung cancer; Immunoscore; STAGE; RECOMMENDATIONS; CLASSIFICATION; IMMUNOSCORE; DENSITY; RECURRENCE; PROGNOSIS; MARKER; IMPACT; TILS;
D O I
10.1016/j.humpath.2018.05.017
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The presence of tumor-infiltrating lymphocytes (TILs) positively impacts the outcome of non- small cell lung cancer (NSCLC) patients. Most previous studies have assessed TILs using different immunohistochemical assays. The purpose of this study was to develop and validate a histopathological scoring model for the assessment of TILs in whole-tissue hematoxylin and eosin (H&E)-stained section slides of NSCLC patients and to evaluate the model in an immunoscore setting. Therefore, TIL was evaluated manually on H&E slides from 537 surgical specimens of primary resected stage I-III NSCLC patients. Using stromal TIL score as a stepwise discrete variable, increasing survival was seen with rising TIL level: disease-specific survival (DSS; P = .008), overall survival (P = .036) and disease-free survival (P = .006). Subgroup analysis revealed that high stromal TILs level was associated with superior DSS (P = .047) in patients with squamous cell carcinoma, but not in patients with adenocarcinoma. Multivariable analysis confirmed that high TIL levels independently predict improved prognosis for all endpoints in the overall cohort. In conclusion, high stromal TIL level is an independent favorable prognostic factor in stage NSCLC patients. The comprehensive histological evaluation conducted in this study may be helpful in streamlining TIL quantification for routine clinical use in a future NSCLC immunoscore setting. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:188 / 198
页数:11
相关论文
共 50 条
  • [1] Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer
    Zhou, Guangrun
    Zheng, Jifang
    Chen, Zhiwei
    Hu, Dan
    Li, Suyu
    Zhuang, Wu
    He, Zhiyong
    Lin, Gen
    Wu, Biao
    Zhang, Wei
    Fang, Weimin
    Zheng, Fei
    Wang, Jiezhong
    Chen, Gang
    Chen, Mingqiu
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [2] Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer
    Wang, X.
    Barrera, C.
    Bera, K.
    Lu, C.
    Feldman, M.
    Schalper, K.
    Rimm, D.
    Velcheti, V.
    Madabhushi, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S350 - S351
  • [3] Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non-Small Cell Lung Cancer
    Sepesi, B.
    Cuentes, E. Parra
    Canales, J. R.
    Behrens, C.
    Correa, A.
    Antonoff, M.
    Gibbons, D. L.
    Heymach, J.
    Hofstetter, W.
    Mehran, R.
    Rice, D. C.
    Roth, J.
    Vaporciyan, A. A.
    Walsh, G.
    Weissferdt, A.
    Kalhor, N.
    Moran, C.
    Swisher, S. G.
    Wistuba, I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 223 - 223
  • [4] Computerized Density Estimation of Tumor-Infiltrating Lymphocyte in H&E TMAs Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer
    Wang, Xiangxue
    Corredor, German
    Romero, Eduardo
    Janowczyk, Andrew
    Zhou, Yu
    Yang, Michael C.
    Velcheti, Vamsidhar
    Madabhushi, Anant
    LABORATORY INVESTIGATION, 2017, 97 : 401A - 402A
  • [5] Computerized Density Estimation of Tumor-Infiltrating Lymphocyte in H&E TMAs Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer
    Wang, Xiangxue
    Corredor, German
    Romero, Eduardo
    Janowczyk, Andrew
    Zhou, Yu
    Yang, Michael C.
    Velcheti, Vamsidhar
    Madabhushi, Anant
    MODERN PATHOLOGY, 2017, 30 : 401A - 402A
  • [6] Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer
    Plaugher, Daniel R.
    Childress, Avery R.
    Gosser, Christian M.
    Esoe, Dave-Preston
    Naughton, Kassandra J.
    Hao, Zhonglin
    Brainson, Christine F.
    CANCER LETTERS, 2024, 605
  • [7] Combined immunophenotyping of tumor-infiltrating lymphocytes as a prognostic factor in resected patients with non-small cell lung cancer
    Soo, Ross A.
    Asuncion, Bernadette Reyna
    Loh, Marie
    Fazreen, Zul
    Sim, Braxton
    Nga, Min En
    Pang, Yin Huei
    Pang, Brendan
    Iacopetta, Barry
    Soong, Richie Chuan Teck
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Prognostic impact of tumor-infiltrating lymphocytes and neutrophils in resected non-small cell carcinoma
    Ishikawa, Ryou
    Kadota, Kyuichi
    Ikeda, Toshihiro
    Yoshida, Chihiro
    Kimura, Nachino
    Ibuki, Emi
    Go, Tetsuhiko
    Yokomise, Hiroyasu
    Haba, Reiji
    HUMAN PATHOLOGY, 2022, 125 : 87 - 96
  • [9] Evaluation of tumor infiltrating lymphocites (TILs) and survival in patients with resected non-small cell lung cancer.
    Cardenas Quesada, Nuria
    Ortega Granados, Ana Laura
    Marquez Lobo, Belgica
    Rosa Garrido, Carmen
    Sanchez Rovira, Pedro
    Nunez Torres, Maria Isabel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer
    Bremnes, Roy M.
    Busund, Lill-Tove
    Kilvaer, Thomas L.
    Andersen, Sigve
    Richardsen, Elin
    Paulsen, Erna Elise
    Hald, Sigurd
    Khanehkenari, Mehrdad Rakaee
    Cooper, Wendy A.
    Kao, Steven C.
    Donnem, Tom
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 789 - 800